2021
Innovation in the treatment of persistent pain in adults with Neurofibromatosis Type 1 (NF1): Implementation of the iCanCope mobile application
Buono FD, Lalloo C, Larkin K, Zempsky WT, Ball S, Grau LE, Pham Q, Stinson J. Innovation in the treatment of persistent pain in adults with Neurofibromatosis Type 1 (NF1): Implementation of the iCanCope mobile application. Contemporary Clinical Trials Communications 2021, 25: 100883. PMID: 35036627, PMCID: PMC8743203, DOI: 10.1016/j.conctc.2021.100883.Peer-Reviewed Original ResearchNeurofibromatosis type 1Pain symptomsNF1 populationType 1Chronic pain symptomsSelf-management treatmentPersistent painTreatment satisfactionTreatment optionsControl studySix weeksPainPsychometric evaluationContingency managementInitial effectivenessGenetic disordersThird groupSymptomsAdultsTreatmentPopulationDifferent populationsGroupParticipants' experiencesGreater reachPercutaneous electrical nerve field stimulation to reduce clinical opiate withdrawal: a case series
Buono F, Pickering R, Berlepsch R, Halligan S. Percutaneous electrical nerve field stimulation to reduce clinical opiate withdrawal: a case series. Journal Of Substance Use 2021, 27: 501-504. DOI: 10.1080/14659891.2021.1961894.Peer-Reviewed Original ResearchClinical Opiate Withdrawal ScaleMedication-assisted treatmentWithdrawal symptomsCase seriesPercutaneous electrical nerve field stimulationOpiate withdrawal symptomsOpioid withdrawal symptomsRetrospective case seriesOpiate use disorderOpiate Withdrawal ScaleCOWS scoresAdult patientsClinical reviewProspective studyClinician interviewsOpiate withdrawalField stimulationWithdrawal ScaleSide effectsUse disordersDay 1Practical nursesDay 5Negative symptomsSymptoms
2020
Sublingual Oxytocin With Clozapine in a Patient With Persisting Psychotic Symptoms, Suicidal Thinking With Self-Harm.
Garakani A, Buono FD, Marotta RF. Sublingual Oxytocin With Clozapine in a Patient With Persisting Psychotic Symptoms, Suicidal Thinking With Self-Harm. Journal Of Clinical Psychopharmacology 2020, 40: 507-509. PMID: 32701906, DOI: 10.1097/jcp.0000000000001248.Peer-Reviewed Case Reports and Technical NotesThe effects of augmenting clozapine with oxytocin in schizophrenia: An initial case series.
Marotta RF, Buono FD, Garakani A, Collins E, Cerrito B, David Rowe DR. The effects of augmenting clozapine with oxytocin in schizophrenia: An initial case series. Annals Of Clinical Psychiatry 2020, 32: 90-96. PMID: 32343282.Peer-Reviewed Case Reports and Technical NotesConceptsTreatment-resistant schizophreniaNegative symptomsAtypical antipsychoticsRetrospective chart reviewInitial case seriesAugmentation of clozapineChronic psychotic illnessNegative Syndrome ScaleYoung adult inpatientsSymptoms of schizophreniaParent/guardian reportsChart reviewCase seriesAdult inpatientsProspective studyAntipsychotic medicationClinical reviewTherapeutic responsePsychotic illnessTreatment approachesSyndrome ScalePositive symptomsTreating psychiatristSymptomsSustained treatment